Synosia Therapeutics has appointed Philippe Lutz as the company’s first chief financial officer, effective immediately. He will be based at the company’s new headquarters in Basel, Switzerland.
Mr Lutz comes from Credit Suisse Investment Banking where he was vice president of the global markets solutions group.
The privately-owned Synosia is developing six clinical-stage compounds acquired through partnerships with Novartis, Roche and Syngenta. Its focus is on neurological and psychiatric diseases.
Source:
Synosia Therapeutics press release, 4 February 2008
Copyright 2008 Evernow Publishing Ltd